H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle

BMC Cell Biology

Xun Xu²  Yi Xu²  Zhongxiao Wang²  Li Su²  Ye Sun¹ 

[1]Department of Biology, Shanghai Institute of Technology, 200235, Shanghai, P.R. China

[2]Department of Ophthalmology, Shanghai First People’s Hospital, Shanghai JiaoTong University, Haining Road 100, 200080, Shanghai, P.R. China

关键词: Neovascularization;    Cornea;    HUVECs;    Peptide;    H-RN;   

Others  :  855494
DOI  :  10.1186/1471-2121-14-8

 received in 2012-09-26, accepted in 2013-02-20,  发布年份 2013

【 摘 要 】

Background

The goal of this study was to investigate the anti-angiogenic activity of a novel peptide H-RN, derived from the hepatocyte growth factor kringle 1 domain (HGF K1), in a mouse model of corneal neovascularization. The anti-angiogenic effect of H-RN on vascular endothelial growth factor (VEGF)-stimulated cell proliferation, cell migration and endothelial cell tube formation was assessed in vitro using Human Umbilical Vein Endothelial Cells (HUVECs) and in vivo using a mouse cornea micropocket assay. Apoptosis and cell cycle arrest were assessed by flow cytometry. A scrambled peptide was used as a negative control.

Results

H-RN effectively inhibited VEGF-stimulated HUVEC proliferation, migration and tube formation on Matrigel, while a scrambled peptide exerted no effect. In the mouse model of corneal angiogenesis, VEGF-stimulated angiogenesis was significantly inhibited by H-RN compared to a scrambled peptide that had no such activity. VEGF protected HUVECs from apoptosis, while H-RN inhibited this protective effect of VEGF. VEGF significantly increased the proportion of cells in the S phase compared to control treated cells (p<0.05). Treatment with H-RN (1.5 mM) induced the accumulation of cells in G0/G1 phase, while the proportion of cells in the S phase and G2/M phase decreased significantly compared to control group (p<0.05).

Conclusions

H-RN has anti-angiogenic activity in HUVECs and in a mouse model of VEGF-induced corneal neovascularization. The anti-angiogenic activity of H-RN was related to apoptosis and cell cycle arrest, indicating a potential strategy for anti-angiogenic treatment in the cornea.

【 授权许可】

   
2013 Sun et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Biswas PS, Rouse BT: Early events in HSV keratitis–setting the stage for a blinding disease. Microbes Infect. 2005, 7:799-810.
• [2]Bock F, Konig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C: Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 2007, 104:336-344.
• [3]Scorcia V, Busin M: Survival of mushroom keratoplasty performed in corneas with postinfectious vascularized scars. Am J Ophthalmol 2012, 153:44-50.
• [4]Li N, Wang X, Wan P, Huang M, Wu Z, Liang X, Liu Y, Ge J, Huang J, Wang Z: Tectonic lamellar keratoplasty with acellular corneal stroma in high-risk corneal transplantation. Mol Vis 2011, 17:1909-1917.
• [5]Han ES, Wee WR, Lee JH, Kim MK: Long-term outcome and prognostic factor analysis for keratolimbal allografts. Graefes Arch Clin Exp Ophthalmol 2011, 249:1697-1704.
• [6]Sennlaub F, Courtois Y, Goureau O: Nitric oxide synthase-II is expressed in severe corneal alkali burns and inhibits neovascularization. Invest Ophthalmol Vis Sci. 1999, 40:2773-2779.
• [7]Lee P, Wang CC, Adamis AP: Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998, 43:245-269.
• [8]Regenfuss B, Bock F, Parthasarathy A, Cursiefen C: Corneal (lymph)angiogenesis–from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 2008, 6:191-201.
• [9]Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R: Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009, 127:381-389.
• [10]Holzer MP, Solomon KD, Vroman DT, Sandoval HP, Margaron P, Kasper TJ, Crosson CE: Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci. 2003, 44:2954-2958.
• [11]van Wijngaarden P, Coster DJ, Williams KA: Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005, 293:1509-1513.
• [12]Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. N Engl J Med 2004, 351:2805-2816.
• [13]Giantonio BJ, Levy DE, O’Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB: A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 2006, 17:1399-1403.
• [14]Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
• [15]Sulochana KN, Ge R: Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 2007, 13:2074-2086.
• [16]Xu Y, Zhao H, Zheng Y, Gu Q, Ma J, Xu X: A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Mol Vis 2010, 16:1982-1995.
• [17]Zhou SY, Xie ZL, Xiao O, Yang XR, Heng BC, Sato Y: Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1. Mol Vis 2010, 16:1389-1398.
• [18]Mutan VR, Auerbach R: Angiogenesis in the mouse cornea. Science 1979, 205:1418-1419.
• [19]Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ: A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996, 37:1625-1632.
• [20]Li T, Hu A, Li S, Luo Y, Huang J, Yu H, Ma W, Pan J, Zhong Q, Yang J, Wu J, Tang S: KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment forcorneal neovascularization. Mol Vis 2011, 17:797-803.
• [21]Prager GW, Mihaly J, Brunner PM, Koshelnick Y, Hoyer-Hansen G, Binder BR: Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 2009, 113:1383-1390.
• [22]Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998, 273:13313-13316.
• [23]Obaya AJ, Sedivy JM: Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci. 2002, 59:126-142.
• [24]Mani S, Wang C, Wu K, Francis R, Pestell R: Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs. 2000, 9:1849-1870.
• [25]Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C: Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006, 70:146-157.
• [26]Yu WZ, Zou H, Li XX, Yan Z, Dong JQ: Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization. Ophthalmic Res. 2008, 40:19-25.
• [27]Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, Ge R: Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 2005, 280:27935-27948.
• [28]Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62:625-631.
• [29]Li J, Chen X, Xiao W, Ma W, Li T, Huang J, Liu X, Liang X, Tang S, Luo Y: Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells. Biochem Biophys Res Commun 2011, 404:349-356.
• [30]Chen JY, Hwang CC, Chen WY, Lee JC, Fu TF, Fang K, Chu YC, Huang YL, Lin JC, Tsai WH, Chang HW, Chen BH, Chiu CC: Additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells. Life Sci 2010, 87:350-357.
• [31]Przygodzka P, Boncela J, Cierniewski CS: Matrin 3 as a key regulator of endothelial cell survival. Exp Cell Res. 2011, 317:802-811.